Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

被引：53

作者：

Nigro, Olga ^{[1
]}

Pinotti, Graziella ^{[1
]}

De Galitiis, Federica ^{[2
]}

Di Pietro, Francesca Romana ^{[2
,3
]}

Giusti, Raffaele ^{[3
]}

Filetti, Marco ^{[3
]}

Bersanelli, Melissa ^{[4
]}

Lazzarin, Alessandro ^{[4
]}

Bordi, Paola ^{[4
]}

Catino, Annamaria ^{[5
]}

Pizzutilo, Pamela ^{[5
]}

Galetta, Domenico ^{[5
]}

Marchetti, Paolo ^{[2
,6
]}

Botticelli, Andrea ^{[6
]}

Scagnoli, Simone ^{[6
]}

Russano, Marco ^{[7
]}

Santini, Daniele ^{[7
]}

Torniai, Mariangela ^{[8
]}

Berardi, Rossana ^{[8
]}

Ricciuti, Biagio ^{[9
]}

De Giglio, Andrea ^{[9
]}

Chiari, Rita ^{[10
]}

Russo, Alessandro ^{[11
]}

Adamo, Vincenzo ^{[11
]}

Tudini, Marianna ^{[12
]}

Silva, Rosa Rita ^{[12
]}

Bolzacchini, Elena ^{[13
]}

Giordano, Monica ^{[13
]}

Di Marino, Pietro ^{[14
]}

De Tursi, Michele ^{[15
]}

Rijavec, Erika ^{[16
]}

Ghidini, Michele ^{[16
]}

Vallini, Ilaria ^{[1
]}

Stucci, Luigia Stefania ^{[17
]}

Tucci, Marco ^{[17
,25
]}

Pala, Laura ^{[18
]}

Conforti, Fabio ^{[18
]}

Queirolo, Paola ^{[18
]}

Tanda, Enrica ^{[19
]}

Spagnolo, Francesco ^{[19
]}

Cecchi, Federica ^{[19
]}

Bracarda, Sergio ^{[20
]}

Macrini, Serena ^{[20
]}

Santoni, Matteo ^{[21
]}

Battelli, Nicola ^{[21
]}

Fargnoli, Maria Concetta ^{[22
,23
]}

Porzio, Giampiero ^{[22
,24
]}

Tuzi, Alessandro ^{[1
]}

Suter, Matteo Basilio ^{[1
]}

Ficorella, Corrado ^{[22
,24
]}

机构：

[1] Osped Circolo & Fdn Macchi, ASST Sette Laghi, Med Oncol, Varese, Italy

[2] IDI IRCCS, Oncol & Oncol Dermatol, Rome, Italy

[3] Azienda Osped Univ St Andrea, Med Oncol, Rome, Italy

[4] Azienda Osped Univ Parma, Med Oncol, Parma, Italy

[5] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Bari, Italy

[6] Univ Roma La Sapienza, Dipartimento Sci Med Chirurg & Med Traslaz, Rome, Italy

[7] Med Oncol, Campus Biomed, Rome, Italy

[8] Univ Politecn Marche, Clin Oncol, Azienda Osped Univ Osped Riuniti Umberto 1, GM Lancisi, Ancona, Italy

[9] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy

[10] Osped Riuniti Padova Sud Madre Teresa Di Calcutta, Med Oncol, Monselice, Italy

[11] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[12] ASUR Marche, Area Vasta 2, Med Oncol, Fabriano, Italy

[13] Osped St Anna, ASST Lariana, Med Oncol, Como, Italy

[14] SS Annunziata Hosp, Clin Oncol Unit, Chieti, Italy

[15] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[16] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Med Oncol Unit, Milan, Italy

[17] Univ Bari, Med Oncol Unit, Dept Biomed Sci & Human Oncol, Bari, Italy

[18] IRCCS, European Inst Oncol, Div Med Oncol Melanoma Sarcoma & Rare Tumors, IEO, Milan, Italy

[19] Osped Policlin San Martino, IRCCS, Genoa, Italy

[20] Santa Maria Hosp, Dept Med Oncol, Terni, Italy

[21] Macerata Hosp, Dept Oncol, Macerata, Italy

[22] St Salvatore Hosp, Dept Dermatol, Laquila, Italy

[23] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[24] St Salvatore Hosp, Med Oncol, Laquila, Italy

[25] Tumori Inst Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 134卷

关键词：

Immunotherapy; Immune checkpoint; Nivolumab; Pembrolizumab; Atezolizumab; Immune-related adverse events; ELDERLY-PATIENTS; CANCER;

D O I：

10.1016/j.ejca.2020.04.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICIs) are lacking. Methods: We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in patients with advanced cancer. IrAEs were categorized into 'early' (<= 12 months) and 'late' (>12 months). Results: From September 2013 to October 2019, 436 consecutive patients were evaluated. Two hundred twenty-three experienced any grade early-irAEs (51.1%), whereas 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, whereas 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced GIII/GIV irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95% confidence interval [CI]: 2.8-4.2), whereas the median time to onset of late-irAEs was 16.6 months (95% CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (hazard ratio [HR] = 0.63 [95% CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95% CI: 0.37-1.56], p = 0.452). In addition, the time-adjusted cumulative risk of death in accordance with both early-irAEs (HR = 0.79 [95% CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95% CI: 0.49-1.74], p = 0.811) did not show statistically significant differences. Conclusion: Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：19 / 28

页数：10

共 37 条

[1] [Anonymous], 2015, J NATL CANC I, DOI DOI 10.1093/JNCI/DJV216
[2] Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Antonia, Scott J.
Borghaei, Hossein
Ramalingam, Suresh S.
Horn, Leora
De Castro Carpeno, Javier
Pluzanski, Adam
Burgio, Marco A.
Garassino, Marina
Chow, Laura Q. M.
Gettinger, Scott
Crino, Lucio
Planchard, David
Butts, Charles
Drilon, Alexander
Wojcik-Tomaszewska, Joanna
Otterson, Gregory A.
Agrawal, Shruti
Li, Ang
Penrod, John R.
Brahmer, Julie
[J]. LANCET ONCOLOGY, 2019, 20 (10) : 1395 - 1408
[3] Trends in kidney cancer among the elderly in Denmark, 1980-2012
Azawi, Nessn H.
Joergensen, Simon Moeller
Jensen, Niels Viggo
Clark, Peter E.
Lund, Lars
[J]. ACTA ONCOLOGICA, 2016, 55 : 79 - 84
[4] Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner, Fiamma
Bomze, David
Diem, Stefan
Ali, Omar Hasan
Faessler, Mirjam
Ring, Sandra
Niederer, Rebekka
Ackermann, Christoph J.
Baumgaertner, Petra
Pikor, Natalia
Cruz, Cristina Gil
van de Veen, Willem
Akdis, Muebeccel
Nikolaev, Sergey
Laeubli, Heinz
Zippelius, Alfred
Hartmann, Fabienne
Cheng, Hung-Wei
Hoenger, Gideon
Recher, Mike
Goldman, Jonathan
Cozzi, Antonio
Fruek, Martin
Neefjes, Jacques
Driessen, Christoph
Ludewig, Burkhard
Hegazy, Ahmed N.
Jochum, Wolfram
Speiser, Daniel E.
Flatz, Lukas
[J]. JAMA ONCOLOGY, 2019, 5 (07) : 1043 - 1047
[5] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, Julie R.
Lacchetti, Christina
Schneider, Bryan J.
Atkins, Michael B.
Brassil, Kelly J.
Caterino, Jeffrey M.
Chau, Ian
Ernstoff, Marc S.
Gardner, Jennifer M.
Ginex, Pamela
Hallmeyer, Sigrun
Chakrabarty, Jennifer Holter
Leighl, Natasha B.
Mammen, Jennifer S.
McDermott, David F.
Naing, Aung
Nastoupil, Loretta J.
Phillips, Tanyanika
Porter, Laura D.
Puzanov, Igor
Reichner, Cristina A.
Santomasso, Bianca D.
Seigel, Carole
Spira, Alexander
Suarez-Almazor, Maria E.
Wang, Yinghong
Weber, Jeffrey S.
Wolchok, Jedd D.
Thompson, John A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
[6] Rheumatic immune-related adverse events from cancer immunotherapy
Calabrese, Leonard H.
Calabrese, Cassandra
Cappelli, Laura C.
[J]. NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (10) : 569 - 579
[7] Distinctive Features of Melanoma and Its Management in Elderly Patients A Population-Based Study in France
Ciocan, Dragos
Barbe, Coralie
Aubin, Francois
Granel-Brocard, Florence
Lipsker, Dan
Velten, Michel
Dalac, Sophie
Truchetet, Francois
Michel, Catherine
Mitschler, Audrey
Arnoult, Gwendoline
Buemi, Antoine
Dalle, Stephane
Bernard, Philippe
Woronoff, Anne-Sophie
Grange, Florent
[J]. JAMA DERMATOLOGY, 2013, 149 (10) : 1150 - 1157
[8] A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients
Cortellini, Alessio
Buti, Sebastiano
Agostinelli, Veronica
Bersanelli, Melissa
[J]. SEMINARS IN ONCOLOGY, 2019, 46 (4-5) : 362 - 371
[9] Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Cortellini, Alessio
Chiari, Rita
Ricciuti, Biagio
Metro, Giulio
Perrone, Fabiana
Tiseo, Marcello
Bersanelli, Melissa
Bordi, Paola
Santini, Daniele
Giusti, Raffaele
Grassadonia, Antonino
Di Marino, Pietro
Tinari, Nicola
De Tursi, Michele
Zoratto, Federica
Veltri, Enzo
Malorgio, Francesco
Garufi, Carlo
Russano, Marco
Anesi, Cecilia
Zeppola, Tea
Filetti, Marco
Marchetti, Paolo
Berardi, Rossana
Rinaldi, Silvia
Tudini, Marianna
Silva, Rosa Rita
Pireddu, Annagrazia
Atzori, Francesco
Iacono, Daniela
Migliorino, Maria Rita
Porzio, Gampiero
Cannita, Katia
Ficorella, Corrado
Buti, Sebastiano
[J]. CLINICAL LUNG CANCER, 2019, 20 (04) : 237 - +
[10] Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Cortellini, Alessio
Buti, Sebastiano
Santini, Daniele
Perrone, Fabiana
Giusti, Raffaele
Tiseo, Marcello
Bersanelli, Melissa
Michiara, Maria
Grassadonia, Antonino
Brocco, Davide
Tinari, Nicola
De Tursi, Michele
Zoratto, Federica
Veltri, Enzo
Marconcini, Riccardo
Malorgio, Francesco
Garufi, Carlo
Russano, Marco
Anesi, Cecilia
Zeppola, Tea
Filetti, Marco
Marchetti, Paolo
Botticelli, Andrea
Antonini Cappellini, Gian Carlo
De Galitiis, Federica
Vitale, Maria Giuseppa
Sabbatini, Roberto
Bracarda, Sergio
Berardi, Rossana
Rinaldi, Silvia
Tudini, Marianna
Silva, Rosa Rita
Pireddu, Annagrazia
Atzori, Francesco
Chiari, Rita
Ricciuti, Biagio
Iacono, Daniela
Migliorino, Maria Rita
Rossi, Antonio
Porzio, Giampiero
Cannita, Katia
Ciciarelli, Valeria
Fargnoli, Maria Concetta
Ascierto, Paolo Antonio
Ficorella, Corrado
[J]. ONCOLOGIST, 2019, 24 (06) : E327 - E337

← 1 2 3 4 →